InterMune Inc. is not for sale — now stop asking.
That’s the takeaway from the Brisbane company’s (NASDAQ: ITMN) first-quarter recap conference call Thursday morning. But sources told Bloomberg and Dealreporter.com this week that the developer of the idiopathic pulmonary fibrosis drug Esbriet has been shopped around for a few weeks. Bloomberg said Goldman Sachs is managing the process.
Showing posts with label Goldman Sachs. Show all posts
Showing posts with label Goldman Sachs. Show all posts
Thursday, April 28, 2011
Tuesday, April 12, 2011
Report: Exelixis hires Goldman Sachs to prepare for takeover offers
Rumors of Exelixis Inc. hiring Goldman Sachs to prepare for possible sale offers sent shares of the South San Francisco cancer drug company higher, according to Bloomberg.
A spokesman for Exelixis (NASDAQ: EXEL) told Bloomberg that the company does not comment on such reports, noting that sale rumors have “been around the company for a long time.”
Exelixis, which had been known for its prodigious pipeline of drugs, has garnered lots of attention over the past five months because of a single drug. The company has opted to focus on XL-184, or cabozantinib, which appears to stop cancerous growth not only in soft tissue but also on bone.
A spokesman for Exelixis (NASDAQ: EXEL) told Bloomberg that the company does not comment on such reports, noting that sale rumors have “been around the company for a long time.”
Exelixis, which had been known for its prodigious pipeline of drugs, has garnered lots of attention over the past five months because of a single drug. The company has opted to focus on XL-184, or cabozantinib, which appears to stop cancerous growth not only in soft tissue but also on bone.
Subscribe to:
Comments (Atom)